Studies Presented at International Society of Minimally Invasive Cardiac Surgery on the Superior Clinical Outcomes Using the ESTECH COBRA(R) Product Line for Cardiac Ablation
Posted on: Thursday, 14 June 2007, 15:20 CDT
During last week's 10th Annual International Society of Minimally Invasive Cardiac Surgery (ISMICS) meeting in Rome, Italy, the COBRA AFfirm Bipolar Pacing Probe was again recognized as the standard of care in successful treatment of Atrial Fibrillation. Mark La Meir, M.D., University Hospital Maastricht in The Netherlands, reported a direct connection between conduction block and successful Surgical Cardiac Ablation.
Dr. La Meir commented in his presentation, "Transmurality equals conduction block, and conduction block must be measured during all surgical ablation procedures as a Standard of Care, thus enhancing the ability to achieve a cure for our Patients."
ESTECH Chief Technical Officer, David Swanson, Ph.D., remarked, "Measuring conduction block has been the standard in the practice of Electrophysiology since the subspecialty's inception over 20 years ago. It is time the same science is applied to Surgical Ablation. Treatment of AF, whether by catheter or surgical technique, must be driven by evidence-based medicine. With the ESTECH AFfirm Bipolar Pacing Probe the measurement of conduction block is simple and very reliable, and with further collaboration between EPs and Surgeons in the COBRA AFfirm Registry, patients will benefit from the best of both techniques."
About ESTECH
Since 1996, ESTECH has pioneered least invasive cardiac surgery techniques with emphasis on least invasive valve procedures and coronary bypass surgery. In 2005, the company received approval to sell the COBRA product line with the Cardiac Ablation indication. The COBRA Bipolar (and all similar Bipolar devices from companies such as Medtronic, Inc. -- MDT, NYSE, and AtriCure, Inc. -- ATRC, NASDAQ) are indicated for Soft Tissue Coagulation. COBRA products are protected by over 100 U.S. issued patents (ref USPTO 7,115,122 and 9,241,754).
Source: Business Wire
Related Articles
- Advanced Technologies Pump Growth Into European Cardiac Rhythm Management Market, Affirms Frost & Sullivan
- Independent Clinical Trial Finds HIFU Surgical Ablation Effective in Treating Atrial Fibrillation
- MIAA To Conduct Workshop on Sudden Cardiac Arrest in Adolescents
- ORLive Presents: Endometrial Ablation Minimally Invasive Alternative to Hysterectomy
- CyberKnife Technology May Provide Non-Invasive Means for Cardiac Ablation
- New Technique Invented By Doctors at Englewood Hospital Minimizes Complications of Cardiac Ablation Procedure
- MedicalCV, Inc. Announces Completion of 1st AtriLaze(TM) Closed-Chest, Robotic Cardiac Ablation Procedure
- ORLive Presents: Minimally Invasive Heart Valve Surgery -- Reduces the Trauma and Pain Associated With Open-Chest Surgery, Improves Patients Quality of Life
- ESTECH Launches AFfirm(TM), First Cardiac Surgery Product Indicated for Use in the Treatment of Atrial Fibrillation
 |
 |
User Comments (0)
RSS Feeds